ES2876409T3 - Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol - Google Patents

Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol Download PDF

Info

Publication number: ES2876409T3
Authority: ES; Spain
Prior art keywords: rlbdh; modified; vector; expression; seq
Prior art date: 2014-04-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES15721097T

Other languages

English (en)

Spanish (es)

Inventor

James Wilson

Daniel Rader

Suryanrayan Somanathan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Pennsylvania Penn

Original Assignee

University of Pennsylvania Penn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-25

Filing date

2015-04-24

Publication date

2021-11-12

2015-04-24 Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn

2021-11-12 Application granted granted Critical

2021-11-12 Publication of ES2876409T3 publication Critical patent/ES2876409T3/es

Status Active legal-status Critical Current

2035-04-24 Anticipated expiration legal-status Critical

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 112
239000000203 mixture Substances 0.000 title description 14
239000013598 vector Substances 0.000 claims abstract description 94
230000014509 gene expression Effects 0.000 claims abstract description 68
238000006467 substitution reaction Methods 0.000 claims abstract description 50
108090000623 proteins and genes Proteins 0.000 claims abstract description 48
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 42
150000001413 amino acids Chemical class 0.000 claims abstract description 39
230000015556 catabolic process Effects 0.000 claims abstract description 27
238000006731 degradation reaction Methods 0.000 claims abstract description 27
235000012000 cholesterol Nutrition 0.000 claims abstract description 25
230000037361 pathway Effects 0.000 claims abstract description 18
241000702421 Dependoparvovirus Species 0.000 claims abstract description 15
230000002452 interceptive effect Effects 0.000 claims abstract description 7
101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims abstract description 5
102000043555 human LDLR Human genes 0.000 claims abstract description 4
101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims abstract 4
102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims abstract 4
241001164825 Adeno-associated virus - 8 Species 0.000 claims description 19
210000000234 capsid Anatomy 0.000 claims description 19
102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 14
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 12
206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 12
201000001386 familial hypercholesterolemia Diseases 0.000 claims description 12
230000001965 increasing effect Effects 0.000 claims description 11
230000001105 regulatory effect Effects 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
210000005229 liver cell Anatomy 0.000 claims description 4
241000699670 Mus sp. Species 0.000 description 48
210000004027 cell Anatomy 0.000 description 44
241001465754 Metazoa Species 0.000 description 24
210000004185 liver Anatomy 0.000 description 24
238000000034 method Methods 0.000 description 24
241000282414 Homo sapiens Species 0.000 description 21
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 21
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 21
230000009467 reduction Effects 0.000 description 21
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 21
239000013603 viral vector Substances 0.000 description 19
230000000694 effects Effects 0.000 description 18
239000013612 plasmid Substances 0.000 description 18
150000007523 nucleic acids Chemical group 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
230000033228 biological regulation Effects 0.000 description 16
108010010234 HDL Lipoproteins Proteins 0.000 description 15
102000015779 HDL Lipoproteins Human genes 0.000 description 15
108010029485 Protein Isoforms Proteins 0.000 description 14
102000001708 Protein Isoforms Human genes 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
230000001404 mediated effect Effects 0.000 description 13
108700019146 Transgenes Proteins 0.000 description 11
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
241000700605 Viruses Species 0.000 description 10
238000001415 gene therapy Methods 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
238000003119 immunoblot Methods 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
239000002245 particle Substances 0.000 description 7
239000013607 AAV vector Substances 0.000 description 6
102000012758 APOBEC-1 Deaminase Human genes 0.000 description 6
108010079649 APOBEC-1 Deaminase Proteins 0.000 description 6
241001068295 Replication defective viruses Species 0.000 description 6
230000006870 function Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000006166 lysate Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
230000002018 overexpression Effects 0.000 description 5
238000004806 packaging method and process Methods 0.000 description 5
238000010361 transduction Methods 0.000 description 5
230000026683 transduction Effects 0.000 description 5
210000002845 virion Anatomy 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
102000016911 Deoxyribonucleases Human genes 0.000 description 4
108010053770 Deoxyribonucleases Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
102000004243 Tubulin Human genes 0.000 description 4
108090000704 Tubulin Proteins 0.000 description 4
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 4
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 4
229940024142 alpha 1-antitrypsin Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000047 product Substances 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000001890 transfection Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
238000012937 correction Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000011577 humanized mouse model Methods 0.000 description 3
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000005457 optimization Methods 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
241000702423 Adeno-associated virus - 2 Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
101710172072 Kexin Proteins 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000004590 computer program Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
210000005220 cytoplasmic tail Anatomy 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000001064 degrader Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000009716 hepatic expression Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
102000004311 liver X receptors Human genes 0.000 description 2
108090000865 liver X receptors Proteins 0.000 description 2
230000004777 loss-of-function mutation Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000002887 multiple sequence alignment Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000003753 real-time PCR Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
102000028561 sterol response element binding proteins Human genes 0.000 description 2
108091009326 sterol response element binding proteins Proteins 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
ULLNJSBQMBKOJH-VIVFLBMVSA-N (3R,4R,5R)-5-[(1R)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxy-3-oxolanol Chemical compound C([C@H]([C@H]1OC([C@@H]([C@H]1OCC=1C=CC=CC=1)O)OCC)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ULLNJSBQMBKOJH-VIVFLBMVSA-N 0.000 description 1
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
241000649045 Adeno-associated virus 10 Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101150026402 DBP gene Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
241000701148 Equine adenovirus Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
241000282575 Gorilla Species 0.000 description 1
101150064935 HELI gene Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102400001240 Inter-alpha-trypsin inhibitor light chain Human genes 0.000 description 1
101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101710081079 Minor spike protein H Proteins 0.000 description 1
101100135848 Mus musculus Pcsk9 gene Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
241000364051 Pima Species 0.000 description 1
101710136297 Protein VP2 Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
238000010162 Tukey test Methods 0.000 description 1
101150008036 UL29 gene Proteins 0.000 description 1
101150099617 UL5 gene Proteins 0.000 description 1
101150011902 UL52 gene Proteins 0.000 description 1
101150033561 UL8 gene Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
230000003321 amplification Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229940073505 ethyl vanillin Drugs 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000002767 hepatic artery Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000051631 human SERPINA1 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
101710121537 mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
-1 parabens Chemical compound 0.000 description 1
229940090668 parachlorophenol Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
235000010241 potassium sorbate Nutrition 0.000 description 1
239000004302 potassium sorbate Substances 0.000 description 1
229940069338 potassium sorbate Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000010242 retro-orbital bleeding Methods 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000004088 simulation Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940044609 sulfur dioxide Drugs 0.000 description 1
235000010269 sulphur dioxide Nutrition 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000023898 viral genome packaging Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000012130 whole-cell lysate Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Virology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ES15721097T 2014-04-25 2015-04-24 Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol Active ES2876409T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461984620P	2014-04-25	2014-04-25
US201462022627P	2014-07-09	2014-07-09
PCT/US2015/027572 WO2015164778A1 (en)	2014-04-25	2015-04-24	Ldlr variants and their use in compositions for reducing cholesterol levels

Publications (1)

Publication Number	Publication Date
ES2876409T3 true ES2876409T3 (es)	2021-11-12

Family

ID=53055129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES15721097T Active ES2876409T3 (es)	2014-04-25	2015-04-24	Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol

Country Status (7)

Country	Link
US (2)	US11555059B2 (2)
EP (2)	EP3919508A1 (2)
JP (3)	JP6741590B2 (2)
BR (1)	BR112016024379A2 (2)
CA (1)	CA2946392A1 (2)
ES (1)	ES2876409T3 (2)
WO (1)	WO2015164778A1 (2)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2016538829A (ja)	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
ES2876409T3 (es)	2014-04-25	2021-11-12	Univ Pennsylvania	Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
WO2015191508A1 (en)	2014-06-09	2015-12-17	Voyager Therapeutics, Inc.	Chimeric capsids
SG11201703148TA (en)	2014-11-05	2017-05-30	Voyager Therapeutics Inc	Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh)	2014-11-14	2025-04-25	沃雅戈治疗公司	调节性多核苷酸
CA3193811A1 (en)	2014-11-14	2016-05-19	Voyager Therapeutics, Inc.	Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh)	2014-12-12	2018-08-24	Voyager Therapeutics, Inc.	用於生产scaav的组合物和方法
WO2016164762A1 (en) *	2015-04-08	2016-10-13	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EA201792500A1 (ru)	2015-05-13	2018-04-30	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Aav-опосредованная экспрессия антител против гриппа и способы их использования
IL303850A (en) *	2015-12-11	2023-08-01	Univ Pennsylvania	Gene therapy for treating familial hypercholesterolemia
JP7046828B2 (ja) *	2016-04-15	2022-04-04	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	滲出型加齢性黄斑変性の治療のための組成物
EP3448987A4 (en)	2016-04-29	2020-05-27	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en)	2016-04-29	2020-04-22	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
CA3024448C (en)	2016-05-18	2025-09-09	Voyager Therapeutics, Inc.	MODULATING POLYNUCLEOTIDES
CA3024449A1 (en)	2016-05-18	2017-11-23	Voyager Therapeutics, Inc.	Compositions and methods of treating huntington's disease
WO2018022511A1 (en)	2016-07-25	2018-02-01	The Trustees Of The University Of Pennsylvania	Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
WO2018044933A1 (en)	2016-08-30	2018-03-08	The Regents Of The University Of California	Methods for biomedical targeting and delivery and devices and systems for practicing the same
KR102738752B1 (ko) *	2016-12-30	2024-12-06	더 트러스티스 오브 더 유니버시티 오브 펜실베니아	페닐케톤뇨증을 치료하기 위한 유전자 치료
US11554147B2 (en) *	2017-02-20	2023-01-17	The Trustees Of The University Of Pennsylvania	Gene therapy for treating familial hypercholesterolemia
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3052487A1 (en)	2017-02-28	2018-09-07	The Trustees Of The University Of Pennsylvania	Influenza vaccines based on aav vectors
JP7455579B2 (ja)	2017-02-28	2024-03-26	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
EP3612205B9 (en) *	2017-04-21	2023-10-04	Precision Biosciences, Inc.	Engineered meganucleases specific for recognition sequences in the pcsk9 gene
EP3618839A4 (en)	2017-05-05	2021-06-09	Voyager Therapeutics, Inc.	COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja)	2017-05-05	2020-06-25	ボイジャーセラピューティクスインコーポレイテッドＶｏｙａｇｅｒＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ハンチントン病治療組成物および方法
JOP20190269A1 (ar)	2017-06-15	2019-11-20	Voyager Therapeutics Inc	بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja)	2017-07-17	2023-02-28	ボイジャーセラピューティクスインコーポレイテッド	軌道アレイガイドシステム
JP7221275B2 (ja)	2017-08-03	2023-02-13	ボイジャーセラピューティクスインコーポレイテッド	Ａａｖを送達するための組成物および方法
US20200263199A1 (en)	2017-09-29	2020-08-20	Voyager Therapeutics, Inc.	Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
TW202413649A (zh)	2017-10-16	2024-04-01	美商航海家醫療公司	肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en)	2017-10-16	2019-04-25	Voyager Therapeutics, Inc.	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US12558434B2 (en)	2018-02-20	2026-02-24	The Trustees Of The University Of Pennsylvania	Compositions for treatment of wet age-related macular degeneration
SG11202011296VA (en)	2018-05-15	2020-12-30	Voyager Therapeutics Inc	Compositions and methods for the treatment of parkinson's disease
US12281321B2 (en)	2018-09-28	2025-04-22	Voyager Therapeutics, Inc.	Frataxin expression constructs having engineered promoters and methods of use thereof
US20220040332A1 (en) *	2018-12-20	2022-02-10	The Trustees Of The University Of Pennsylvania	Gene therapy for treating familial hypercholesterolemia
JP2023518415A (ja) *	2020-03-19	2023-05-01	ウルトラジェニックスファーマシューティカルインコーポレイテッド	組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法
WO2021222653A1 (en) *	2020-04-29	2021-11-04	Saliogen Therapeutics, Inc.	Compositions and methods for treatment of familial hypercholesterolemia and elevated low-density lipoprotein cholesterol
US20230304034A1 (en)	2020-05-12	2023-09-28	The Trustees Of The University Of Pennsylvania	Compositions for drg-specific reduction of transgene expression
IL300410A (en)	2020-08-14	2023-04-01	Univ Pennsylvania	Novel AAV capsids and compositions containing them
AU2021369793A1 (en)	2020-10-29	2023-06-08	The Trustees Of The University Of Pennsylvania	Aav capsids and compositions containing same
TW202237850A (zh)	2020-12-01	2022-10-01	賓州大學委員會	具有組織特異性靶向基序的新穎構成物及含有其之組成物
AR125406A1 (es)	2021-04-23	2023-07-12	Univ Pennsylvania	Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
TW202309066A (zh)	2021-04-27	2023-03-01	賓州大學委員會	衍生自豬的腺相關病毒衣殼及其用途
CN113684215A (zh) *	2021-09-07	2021-11-23	华中科技大学同济医学院附属协和医院	高胆固醇血症相关的新突变基因及其应用
EP4409010A1 (en)	2021-10-02	2024-08-07	The Trustees of The University of Pennsylvania	Novel aav capsids and compositions containing same
WO2023087019A2 (en)	2021-11-15	2023-05-19	The Trustees Of The University Of Pennsylvania	Compositions for drg-specific reduction of transgene expression
WO2024015966A2 (en)	2022-07-15	2024-01-18	The Trustees Of The University Of Pennsylvania	Recombinant aav having aav clade d and clade e capsids and compositions containing same
AR133098A1 (es)	2023-06-29	2025-08-27	Univ Pennsylvania	Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
WO2025231085A1 (en)	2024-04-30	2025-11-06	Airna Corporation	Site-directed editing of rna

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en)	1992-06-03	2001-07-31	Richard Jude Samulski	Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en)	1992-12-04	1999-02-09	The University Of Pittsburgh	Recombinant viral vector system
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US6204059B1 (en)	1994-06-30	2001-03-20	University Of Pittsburgh	AAV capsid vehicles for molecular transfer
US5817789A (en) *	1995-06-06	1998-10-06	Transkaryotic Therapies, Inc.	Chimeric proteins for use in transport of a selected substance into cells
US5741683A (en)	1995-06-07	1998-04-21	The Research Foundation Of State University Of New York	In vitro packaging of adeno-associated virus DNA
US6093570A (en)	1995-06-07	2000-07-25	The University Of North Carolina At Chapel Hill	Helper virus-free AAV production
WO1998046728A1 (en)	1997-04-14	1998-10-22	Cell Genesys, Inc.	Methods for increasing the efficiency of recombinant aav product
WO1999061643A1 (en)	1998-05-27	1999-12-02	University Of Florida	Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
ES2340230T3 (es)	1998-11-10	2010-05-31	University Of North Carolina At Chapel Hill	Vectores viricos y sus procedimientos de preparacion y administracion.
PT1916258E (pt)	1999-08-09	2014-07-29	Genzyme Corp	Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
AU7879000A (en) *	1999-10-12	2001-04-23	University Of North Carolina At Chapel Hill, The	Adeno-associated virus vectors encoding factor viii and methods of using the same
US7201898B2 (en)	2000-06-01	2007-04-10	The University Of North Carolina At Chapel Hill	Methods and compounds for controlled release of recombinant parvovirus vectors
NZ532635A (en)	2001-11-13	2007-05-31	Univ Pennsylvania	A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en)	2001-12-17	2019-04-15	Univ Pennsylvania	Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en)	2002-06-05	2003-12-22	University Of Florida	Production of pseudotyped recombinant aav virions
CN1856576B (zh)	2003-09-30	2011-05-04	宾夕法尼亚州立大学托管会	腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
CN101018858A (zh)	2004-06-01	2007-08-15	建新公司	防止aav载体聚集的组合物和方法
WO2006110689A2 (en)	2005-04-07	2006-10-19	The Trustees Of The University Of Pennsylvania	Method of increasing the function of an aav vector
EP1777906A1 (en)	2005-06-09	2007-04-25	Matsushita Electric Industrial Co., Ltd.	Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7943374B2 (en) *	2005-08-21	2011-05-17	Markus Hildinger	Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
EP1986737A1 (en)	2006-02-24	2008-11-05	Kenergy Inc	Class-e radio frequency amplifier for use with an implantable medical device
US7588772B2 (en)	2006-03-30	2009-09-15	Board Of Trustees Of The Leland Stamford Junior University	AAV capsid library and AAV capsid proteins
KR101010352B1 (ko)	2008-05-30	2011-01-25	삼성중공업 주식회사	전력 제어 장치 및 방법
BRPI1007155A2 (pt)	2009-01-29	2017-05-30	Univ Of California San Francisco	métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
US20120252877A1 (en)	2009-08-14	2012-10-04	Theramind Research, Llc	Methods and compositions for treatment of tuberous sclerosis complex
DK2529020T3 (en)	2010-01-28	2018-08-06	Childrens Hospital Philadelphia	SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
US20130023033A1 (en)	2010-03-29	2013-01-24	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
US9315825B2 (en)	2010-03-29	2016-04-19	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
EP2721063A4 (en)	2011-06-20	2015-01-14	Hoffmann La Roche	PCSK9 BINDING POLYPEPTIDES AND METHOD OF USE THEREOF
FR2977562B1 (fr)	2011-07-06	2016-12-23	Gaztransport Et Technigaz	Cuve etanche et thermiquement isolante integree dans une structure porteuse
ES2857773T5 (es)	2011-08-24	2024-06-04	Univ Leland Stanford Junior	Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
ES2992345T3 (es)	2011-09-16	2024-12-11	Regeneron Pharma	Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
CA2863964C (en) *	2012-02-07	2021-10-26	Global Bio Therapeutics Usa, Inc.	Compartmentalized method of nucleic acid delivery and compositions and uses thereof
AU2013221212B2 (en)	2012-02-17	2018-08-09	The Children's Hospital Of Philadelphia	AAV vector compositions and methods for gene transfer to cells, organs and tissues
WO2014089212A1 (en) *	2012-12-05	2014-06-12	Sangamo Biosciences, Inc.	Methods and compositions for regulation of metabolic disorders
US9567376B2 (en)	2013-02-08	2017-02-14	The Trustees Of The University Of Pennsylvania	Enhanced AAV-mediated gene transfer for retinal therapies
AU2014216160B2 (en)	2013-02-15	2017-03-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	AAV8 retinoschisin expression vector for treating X-linked retinoschisis
US9254332B2 (en)	2013-03-15	2016-02-09	Arecor Limited	Stable aqueous formulations of adenovirus vectors
SI2984166T1 (sl) *	2013-03-15	2020-09-30	The Trustees Of The University Of Pennsylvania	Sestavki za zdravljenje MPSI
US9719106B2 (en)	2013-04-29	2017-08-01	The Trustees Of The University Of Pennsylvania	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US20150065556A1 (en) *	2013-08-05	2015-03-05	Whitehead Institute For Biomedical Research	Therapeutic targets for mitochondrial disorders
JP2016538829A (ja) *	2013-10-03	2016-12-15	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	低密度リポタンパク質受容体をコードするポリヌクレオチド
ES2876409T3 (es)	2014-04-25	2021-11-12	Univ Pennsylvania	Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
WO2017100676A1 (en)	2015-12-11	2017-06-15	The Trustees Of The University Of Pennsylvania	Scalable purification method for aav8
IL303850A (en)	2015-12-11	2023-08-01	Univ Pennsylvania	Gene therapy for treating familial hypercholesterolemia
US11554147B2 (en)	2017-02-20	2023-01-17	The Trustees Of The University Of Pennsylvania	Gene therapy for treating familial hypercholesterolemia

2015
- 2015-04-24 ES ES15721097T patent/ES2876409T3/es active Active
- 2015-04-24 CA CA2946392A patent/CA2946392A1/en active Pending
- 2015-04-24 BR BR112016024379A patent/BR112016024379A2/pt active Search and Examination
- 2015-04-24 JP JP2016564200A patent/JP6741590B2/ja active Active
- 2015-04-24 WO PCT/US2015/027572 patent/WO2015164778A1/en not_active Ceased
- 2015-04-24 EP EP21166865.2A patent/EP3919508A1/en not_active Withdrawn
- 2015-04-24 US US15/306,419 patent/US11555059B2/en active Active
- 2015-04-24 EP EP15721097.2A patent/EP3134431B1/en active Active
2020
- 2020-04-17 JP JP2020074046A patent/JP7280853B2/ja active Active
2022
- 2022-11-16 US US18/055,928 patent/US20230272032A1/en not_active Abandoned
2023
- 2023-05-12 JP JP2023078988A patent/JP2023100960A/ja active Pending

Also Published As

Publication number	Publication date
US11555059B2 (en)	2023-01-17
US20230272032A1 (en)	2023-08-31
JP2023100960A (ja)	2023-07-19
BR112016024379A2 (pt)	2017-10-10
JP2017513504A (ja)	2017-06-01
CA2946392A1 (en)	2015-10-29
EP3134431A1 (en)	2017-03-01
JP6741590B2 (ja)	2020-08-19
EP3134431B1 (en)	2021-04-07
JP7280853B2 (ja)	2023-05-24
EP3919508A1 (en)	2021-12-08
JP2020120673A (ja)	2020-08-13
US20170101458A1 (en)	2017-04-13
WO2015164778A1 (en)	2015-10-29

Publication	Publication Date	Title
ES2876409T3 (es)	2021-11-12	Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
US12569525B2 (en)	2026-03-10	Gene therapy for treating phenylketonuria
JP6978407B2 (ja)	2021-12-08	Ｇｌｐ−１及び代謝性疾患を治療するための組成物におけるその使用
EP3116900B1 (en)	2020-07-08	Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
ES2989774T3 (es)	2024-11-27	Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos
ES2970293T3 (es)	2024-05-27	Variantes de alfa-glucosidasa ácida y usos de las mismas
JP7061067B2 (ja)	2022-04-27	クリグラー・ナジャー症候群の処置のための組成物
TW202216244A (zh)	2022-05-01	有用於治療夏馬杜三氏病之組成物
JP2025508981A (ja)	2025-04-10	インスリン融合タンパク質をコードするウイルスベクターゲノム
US20260077061A1 (en)	2026-03-19	Compositions and methods for in vivo nuclease-mediated gene targeting for the treatment of genetic disorders in adult patients
WO2023140971A1 (en)	2023-07-27	Methods for treatment of ornithine transcarbamylase (otc) deficiency
BR122023017012B1 (pt)	2026-02-10	Polipeptídeo de alfa-glicosidade ácida humana (hgaa) truncado